- Company
- General hospitals clear Norvasc for pediatric use
- by Eo, Yun-Ho Jan 28, 2020 11:18am
- More general hospitals are reportedly listing Norvasc on their drug codes for pediatric treatment. Pharmaceutical industry on Jan. 28 said respective Drug Committees in Seoul National University Hospital, Severance Hospital and Korea University Guro Hospital cleared Norvasc (Amlodipine) 2.5 mg for prescription from the release in last ye
- Policy
- Tarlige, pain reliever & Smyraf, RA treatment approved
- by Lee, Tak-Sun Jan 28, 2020 06:13am
- New drugs such as Tarlige (Mirogabalin besylate by Daiichi Sankyo, Korea) used for the treatment of peripheral neuropathic pain and Smyraf (Peficitinib hydrobromide, Korea Astellas Pharmaceutical) for rheumatoid arthritis received domestic permission at the same time . They are expected to compete with existing products of the same family
- Company
- Repatha’s options for ultra high risk patients extended
- by Eo, Yun-Ho Jan 28, 2020 06:13am
- Since statins, the coverage of the PCK9 inhibitor Repatha, an option for managing dyslipidemia, is expected to increase utilization. Amgen Korea(the CEO Noh) held a press conference at the Westin Chosun Hotel in Seoul on the 22nd to commemorate the reinforcement of health insurance benefits for Repatha’s atherosclerotic cardiovascular dis
- Company
- Last year, Tamiflu sales fell by half
- by Jung, Hye-Jin Jan 28, 2020 06:13am
- Last year, the flu treatment Tamiflu market dropped sharply. The size of the market has shrunk as the number of flu patients has decreased significantly from 2018. The share of generics in the market has been expanding. Outpatient prescription performance of Oseltamivir were down &8361;17.2 billion, down 50.4% from last year, according to UB
- Policy
- Finally a complete revision of PE guideline after 8 years?
- by Lee, Hye-Kyung Jan 28, 2020 06:12am
- After long eight years, the Korean health authority seems to finally accept the pharmaceutical industry’s demand to amend the pharmacoeconomic analysis guideline. Health Insurance Review and Assessment Service (HIRA) recently unveiled a final report on the cosigned research regarding ‘Pharmacoeconomic (PE) Analysis Guideline Revision Plan
- Company
- Yuhan talks plans after lazertinib L/O at JPM Conference
- by Jung, Hye-Jin Jan 28, 2020 06:12am
- Yuhan announced on Jan. 22, the company has participated in J.P. Morgan Healthcare Conference 2020 to talk about plans following the out-licensing lazertinib and to hold R&D recruiting event. Since 2018, Yuhan has signed 3.5 trillion won worth of out-licensing deals including lazertinib. And at the event in the U.S., the company represen
- Company
- Sanofi firing employee for playing golf is unfair dismissal
- by Eo, Yun-Ho Jan 23, 2020 06:16am
- A government organization has decided a salesperson fired by Sanofi Pasteur for playing golf with his colleagues during their working time was unfair dismissal. Following the decision made by Chungnam Regional Labor Relations Commission in 2019, National Labor Relations Commission (NLRC) has accepted “Manager A”’s request for unfair
- Policy
- Unfair profit of orphan drugs will be readjusted
- by Lee, Jeong-Hwan Jan 23, 2020 06:15am
- The KOEDC (Korea Orphan & Essential Drug Center) took the first step toward improving the 'profit for difference' of urgently imported drugs, which had been disputed for over 20 years. The KOEDC will soon discuss the detailed procedures for drug price adjustments with the Ministry of Health and Welfare & the HIRA, for the purpose of perman
- Company
- Lilly Korea, certified as a family-friendly company
- by Eo, Yun-Ho Jan 23, 2020 06:15am
- Lilly Korea (CEO Alberto Riva) said it has succeeded for receiving the family-friendly company certification, which is given to companies that run family-friendly models, for 10 consecutive years by the Ministry of Gender Equality and Family. The Family-Friendly Certification System, through the screening of the Ministry of Gender Equality
- Policy
- SK Chemicals’ hemophilia drug Afstyla wins MFDS approval
- by Lee, Tak-Sun Jan 23, 2020 06:15am
- Hemophilia treatment Afstyla, developed by SK Chemicals, has won an approval for sales in Korea. The drug has licensed out its technology to Australia-based CSL in 2009. Ministry of Food and Drug Safety (MFDS) has authorized commercialization of Afstyla (lonoctocog Alfa (recombinant Factor VIII)) on Jan. 20. The licenser is Zanovex Korea
